Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Bee product could tame fatty liver and blood fats

NCT ID NCT07692438

Disease control Sponsor: Taipei Medical University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 09, 2026 · Last updated Jul 10, 2026 · Updated 1 time

Summary

This study tests whether Taiwan green propolis, a natural bee product, can improve blood lipids and body fat in adults with metabolic dysfunction-associated steatotic liver disease (MASLD), a common fatty liver condition linked to obesity and high cholesterol. About 60 participants take either propolis capsules or placebo for 12 weeks, with measurements of cholesterol, body composition, liver fat, and other metabolic markers. The goal is to see if this supplement offers a safe, effective way to manage metabolic health in people with fatty liver.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Taiwan green propolis extract
What this could lead to
If effective, this natural supplement could offer a safe, accessible way to manage blood lipids and body fat in people with fatty liver disease.
What could go wrong
This is a small, early-stage trial with only 60 participants. The supplement may show no benefit over placebo, and results may not apply to all populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2025

Expected to finish

Sep 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 18 to 80 years * Diagnosis of hepatic steatosis (fatty liver) confirmed by abdominal ultrasound, PLUS at least one of the following metabolic risk factors: 1. Overweight or obesity: BMI \>= 23 kg/m\^2 2. Elevated waist circumference: \>= 90 cm in men or \>= 80 cm in women (South Asian and Chinese criteria) 3. Dysglycemia or type 2 diabetes: prediabetes (HbA1c 5.7-6.4%, or fasting glucose 100-125 mg/dL, or OGTT 2-hour glucose 140-199 mg/dL) OR type 2 diabetes (HbA1c \>= 6.5%, or fasting glucose \>= 126 mg/dL, or OGTT 2-hour glucose \>= 200 mg/dL, or current pharmacological treatment for type 2 diabetes) 4. Elevated triglycerides: \>= 150 mg/dL or currently on lipid-lowering therapy 5. Low HDL-C: \<= 39 mg/dL in men or \<= 50 mg/dL in women, or currently on lipid-lowering therapy 6. Elevated blood pressure: \>= 130/85 mmHg or currently on antihypertensive treatment Exclusion Criteria: * Known allergy to honey, propolis, multiple pollens, or alcohol * Psychiatric disorder or cognitive impairment * Currently pregnant or breastfeeding * Significant endocrine abnormality, or major disease of the heart, liver (other than MASLD), or kidney * Difficulty swallowing capsules * Dementia, impaired consciousness, or inability to respond to questionnaires

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Dyslipidemia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Dyslipidemias fatty liver disease inherited lipid metabolism disorder metabolic dysfunction-associated steatotic liver disease Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Dyslipidemia Metabolic dysfunction-associated steatotic liver disease Non-alcoholic fatty liver disease (NAFLD) Obesity & overweight

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation

    RECRUITING

    Dalin, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.